Where things stand (November 2026): an FDA advisory committee has recommended allowing pharmacies to compound six popular peptides, including BPC-157 and TB-500. That vote is advice, not a rule change. As of our last review, the FDA had not added any of them to its compounding list, and none of them is an FDA-approved drug.
Timeline
| Date | What happened |
|---|---|
| 2023 | The FDA placed 19 peptide-related substances, including BPC-157, in “Category 2” of its interim compounding policy, the group it flagged for potential significant safety risks. In practice, pharmacies stopped compounding them. |
| April 15, 2026 | The FDA announced it would remove 12 of those peptides from Category 2 after their nominations were withdrawn. Removal did not make them eligible for compounding. |
| July 23–24, 2026 | The Pharmacy Compounding Advisory Committee (PCAC) reviewed seven peptides. It voted to recommend six for the 503A bulks list: BPC-157, KPV, TB-500, MOTS-c, Semax and Epitalon. It voted against Emideltide (DSIP). Several votes were close; BPC-157 passed 8 to 6 with one abstention. |
| Next | The FDA decides whether to follow the committee. Adding a substance to the list requires formal rulemaking with public comment, which takes time. FDA staff had recommended against listing all seven. |
What the terms mean
- 503A pharmacy: a state-licensed compounding pharmacy that fills prescriptions for individual patients.
- 503A bulks list: the FDA’s list of ingredients those pharmacies may compound with when there is no approved drug or official monograph.
- Category 2: an interim label for nominated ingredients the FDA believed raised significant safety concerns.
- PCAC: outside experts who advise the FDA. The agency usually considers their advice but isn’t bound by it.
What this means for you
- A committee recommendation is not FDA approval, and it is not proof that a peptide works. The committee reviewed BPC-157 for one specific use, ulcerative colitis.
- Until the FDA finishes rulemaking, the legal status of compounding these peptides remains uncertain. A licensed prescriber and pharmacy can tell you what they can lawfully provide today.
- “Research use only” vials sold online were not part of this process. The vote did nothing to make them safe or lawful to inject.
- FDA-approved peptide medicines such as semaglutide and tirzepatide are a separate matter with their own rules.
New to the topic? Start with what peptides are, then see how to find a legitimate provider.
Educational only. This page is general information, not medical or legal advice, and it does not include dosing instructions. Talk to a licensed clinician before starting, changing or stopping any treatment. Rules change, so check the date on this page.
Sources
- FDA: Bulk drug substances used in compounding under Section 503A
- Polsinelli: What FDA’s latest actions mean for peptide compounding (April 2026)
- Buchanan Ingersoll & Rooney: FDA PCAC recommends six peptides for the 503A bulks list (July 2026)
- Restore Health Consulting: PCAC vote breakdown, peptide by peptide